United Statesimmunisbiomedical.com
Immunis, Inc. is a biotechnology company developing immune‑modulating, regenerative biologic therapies. Its research focuses on cell‑secreted protein compositions (the secretome)—including cytokines and growth factors—intended to rebalance immune signaling and support tissue maintenance in disorders associated with inflammation and age‑ or disease‑related decline.
The company advances off‑the‑shelf, protein‑based therapeutic candidates with potential application in degenerative and atrophic conditions. Activities span discovery, translational research, and process development aimed at scalable, well‑characterized manufacturing of biologic products.
None yet. When a new project in the record names Immunis as owner, partner or investor, it shows here.
Nalfurafine HCl (TRK‑820) will be developed as IMM02‑KORA for L‑dopa‑induced dyskinesia; IND filed Feb 2026 for Phase I. Rights cover US, Canada, EU and EFTA; deal includes upfront, milestones and royalties.
